KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Interest & Investment Income: 2013-2025

Historic Interest & Investment Income for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $6.2 million.

  • Xenon Pharmaceuticals' Interest & Investment Income fell 39.92% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year decrease of 25.00%. This contributed to the annual value of $41.9 million for FY2024, which is 51.86% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Interest & Investment Income is $6.2 million, which was down 13.79% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Interest & Investment Income ranged from a high of $11.4 million in Q1 2024 and a low of $57,000 during Q3 2021.
  • Its 3-year average for Interest & Investment Income is $8.3 million, with a median of $8.1 million in 2025.
  • In the last 5 years, Xenon Pharmaceuticals' Interest & Investment Income plummeted by 92.11% in 2021 and then surged by 5,278.95% in 2022.
  • Over the past 5 years, Xenon Pharmaceuticals' Interest & Investment Income (Quarterly) stood at $191,000 in 2021, then soared by 2,236.65% to $4.5 million in 2022, then soared by 94.73% to $8.7 million in 2023, then grew by 8.41% to $9.4 million in 2024, then slumped by 39.92% to $6.2 million in 2025.
  • Its last three reported values are $6.2 million in Q3 2025, $7.2 million for Q2 2025, and $8.1 million during Q1 2025.